Eli Manning, Hall of Fame
Digest more
Eli Manning has taken another step toward football immortality. The longtime New York Giants quarterback was named a finalist for the Pro Football Hall of Fame Class of 2026. Manning is one of 15 modern-era players still under consideration.
24/7 Wall St. on MSN
Why Eli Lilly is the unexpected must-buy dividend powerhouse to own in 2026
Quick Read Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share.
But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion in revenue. Wegovy generated approximately $9 billion -- despite having been approved in the U.S. more than two years before its competitor.
CLICK HERE AND JOIN FOR JUST $1 + a free year of The Athletic Vanderbilt’s star Tight End Eli Stowers is officially opting out of the upcoming Reliaquest Bowl to prepare for the NFL Draft. The Commodores will be taking on the 8-4 Iowa Hawkeyes on December 31st without their leading pass catcher from the
Mizzou missed its offensive coordinator on Saturday night. A 13-7 loss to Virginia in the TaxSlayer Gator Bowl featured a hard-to-stomach offensive display from the Tigers, who closed out their season with a fifth loss in their final 8 games.
No. 6 Ole Miss (12-1, 7-1 SEC) will hit the road to New Orleans (La.) for a New Year's Day matchup against the Georgia Bulldogs in the AllState Sugar Bowl after
Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than two months.
On Dec. 15, Sharabi spread light in Miami Beach during the American Friends of Magen David Adom Miami Gala held at the Miami Beach Convention Center.
Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market.